Bouffées de chaleur, tamoxifène et cytochrome P450 2D6
作者： G. Boutet
DOI: 10.1007/S10269-012-2170-9
关键词:
摘要: Le cytochrome P450 2D6 (CYP2D6) est un enzyme cle de la transformation du tamoxifene (TAM) en ses deux derives les plus actifs, le 4-hydroxy-TAM et l’endoxifene. L’hypothese qu’un polymorphisme genetique CYP2D6 et/ou prise concomitante medicaments inhibiteurs cet puissent modifier sous TAM a fois frequence l’intensite des bouffees chaleur (BdC) d’une part, l’efficacite therapeutique antineoplasique d’autre fait l’objet conclusions discordantes dans litterature disponible. Il n’y pas actuellement recommandation officielle au genotypage avant prescription alors qu’une commune l’Afssaps l’INCa contreindique coprescription paroxetine fluoxetine avec TAM.
springer.com
sci-hub.se 参考文章(34)
Timothy L Lash, Ernst A Lien, Henrik Toft Sørensen, Stephen Hamilton-Dutoit, Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncology. ,vol. 10, pp. 825- 833 ,(2009) , 10.1016/S1470-2045(09)70030-0
Alastair M Thompson, Andrea Johnson, Philip Quinlan, Grantland Hillman, Marcel Fontecha, Susan E Bray, Colin A Purdie, Lee B Jordan, Roberta Ferraldeschi, Ayshe Latif, Kirsten D Hadfield, Robert B Clarke, Linda Ashcroft, D Gareth Evans, Anthony Howell, Michele Nikoloff, Jeffrey Lawrence, William G Newman, None, Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy Breast Cancer Research and Treatment. ,vol. 125, pp. 279- 287 ,(2011) , 10.1007/S10549-010-1139-X
T. P. Ahern, L. Pedersen, D. P. Cronin-Fenton, H. T. Sorensen, T. L. Lash, No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications Cancer Epidemiology, Biomarkers & Prevention. ,vol. 18, pp. 2562- 2564 ,(2009) , 10.1158/1055-9965.EPI-09-0516
Matthew P. Goetz, Stacey K. Knox, Vera J. Suman, James M. Rae, Stephanie L. Safgren, Matthew M. Ames, Daniel W. Visscher, Carol Reynolds, Fergus J. Couch, Wilma L. Lingle, Richard M. Weinshilboum, Emily G. Barr Fritcher, Andrea M. Nibbe, Zeruesenay Desta, Anne Nguyen, David A. Flockhart, Edith A. Perez, James N. Ingle, The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment. ,vol. 101, pp. 113- 121 ,(2007) , 10.1007/S10549-006-9428-0
Kostandinos Sideras, James N. Ingle, Matthew M. Ames, Charles L. Loprinzi, David P. Mrazek, John L. Black, Richard M. Weinshilboum, John R. Hawse, Thomas C. Spelsberg, Matthew P. Goetz, Coprescription of Tamoxifen and Medications That Inhibit CYP2D6 Journal of Clinical Oncology. ,vol. 28, pp. 2768- 2776 ,(2010) , 10.1200/JCO.2009.23.8931
Hiltrud Brauch, Thomas E Mürdter, Michel Eichelbaum, Matthias Schwab, Pharmacogenomics of Tamoxifen Therapy Clinical Chemistry. ,vol. 55, pp. 1770- 1782 ,(2009) , 10.1373/CLINCHEM.2008.121756
C. M Kelly, D. N Juurlink, T. Gomes, M. Duong-Hua, K. I Pritchard, P. C Austin, L. F Paszat, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ. ,vol. 340, ,(2010) , 10.1136/BMJ.C693
J M Rae, , M J Sikora, N L Henry, L Li, S Kim, S Oesterreich, T C Skaar, A T Nguyen, Z Desta, A M Storniolo, D A Flockhart, D F Hayes, V Stearns, Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics Journal. ,vol. 9, pp. 258- 264 ,(2009) , 10.1038/TPJ.2009.14
Joanne E. Mortimer, Shirley W. Flatt, Barbara A. Parker, Ellen B. Gold, Linda Wasserman, Loki Natarajan, John P. Pierce, , Tamoxifen, hot flashes and recurrence in breast cancer Breast Cancer Research and Treatment. ,vol. 108, pp. 421- 426 ,(2008) , 10.1007/S10549-007-9612-X
L Madlensky, SW Flatt, L Natarajan, H Lawrence, D Nikoloff, M Fontecha, S Hao, G Hillman, A Johnson, BA Parker, JP Pierce, Hot flashes are associated with CYP2D6 genotype in breast cancer survivors taking tamoxifen. Cancer Research. ,vol. 69, pp. 6045- ,(2009) , 10.1158/0008-5472.SABCS-6045